Mei Ri Jing Ji Xin Wen·2025-06-24 13:42Mergers and Acquisitions - Unimed Pharmaceutical announced that its wholly-owned subsidiary, Shanghai Unimed, plans to increase its capital by 45 million yuan to acquire a 51% stake in Sichuan Gokang Pharmaceutical Co., Ltd. After the completion of this transaction, Gokang Pharmaceutical will become a controlled subsidiary of Shanghai Unimed. This transaction does not constitute a related party transaction or a major asset restructuring [1] - BOE Technology Group announced that it has signed a share transfer agreement with Rainbow Co., Ltd. to acquire a 30% stake in Xianyang Rainbow Optoelectronics Technology Co., Ltd. for 4.849 billion yuan [2] - Jianlong Micro-Nano announced that it is planning to acquire at least 51% of Shanghai Hanxing Energy Technology Co., Ltd. through cash payment for equity transfer. Upon completion of this transaction, Jianlong Micro-Nano will become the controlling shareholder of the target company [3] Shareholding Changes - Lishang Guochao announced that its shareholder, Honglou Group Co., Ltd., plans to reduce its holdings by no more than 2.11% of the company's shares, equivalent to a maximum of 16.0764 million shares [4] - Tenglong Co., Ltd. announced that a concerted party of its actual controller, Jiang Yilin, intends to reduce its holdings by no more than 3% of the company's shares, with a maximum of 4.908 million shares through centralized bidding and 9.816 million shares through block trading [5] - Galaxy Microelectronics announced that its major shareholder's concerted parties, Yinjian Investment and Yingu Investment, plan to reduce their holdings by no more than 1.46% of the company's shares, totaling up to 1.8823 million shares. Additionally, director Meng Lang plans to reduce his holdings by no more than 2,250 shares [6] Risk Matters - Zhaofeng Co., Ltd. stated that its current operating conditions are normal and there are no undisclosed significant matters. The company's stock price has experienced an abnormal fluctuation, with a cumulative increase of over 30% in the closing price over three consecutive trading days [7] - Zhejiang Dongri issued a risk warning, clarifying that its daily operations do not involve "brain-computer interface" business. The company has a 40% stake in Peianmei (Zhejiang) Technology Co., Ltd., which has had discussions with Capital Medical University but has not formed a written cooperation agreement [8] - Zhongjing Electronics confirmed that it does not violate information disclosure regulations. The company has experienced an abnormal fluctuation in stock price, with a cumulative increase of over 20% over three consecutive trading days, but its recent operating conditions remain normal [9][10]